{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:38:48Z","timestamp":1772026728864,"version":"3.50.1"},"update-to":[{"DOI":"10.1038\/leu.2015.240","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"record-id":"58036"},{"DOI":"10.1038\/leu.2015.240","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000}}],"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41375-024-02443-z","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T07:02:48Z","timestamp":1729580568000},"page":"2739-2739","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide"],"prefix":"10.1038","volume":"38","author":[{"given":"H.","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Dasilva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Adrian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. C.","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. -T.","family":"Tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"2443_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3389\/fonc.2014.00241","volume":"4","author":"A Gozzetti","year":"2014","unstructured":"Gozzetti A, Candi V, Papini G, Bocchia M. Therapeutic advancements in multiple myeloma. Front Oncol. 2014;4:241.","journal-title":"Front Oncol"},{"key":"2443_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrclinonc.2014.200","volume":"12","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Richardson PG, Moreau P, Anderson KC. Current treatment landscape for relapsed and\/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015;12:42\u201354.","journal-title":"Nat Rev Clin Oncol"},{"key":"2443_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1586\/14737140.2014.863153","volume":"14","author":"R Castelli","year":"2014","unstructured":"Castelli R, Orofino N, Losurdo A, Gualtierotti R, Cugno M. Choosing treatment options for patients with relapsed\/refractory multiple myeloma. Expert Rev Anticancer Ther. 2014;14:199\u2013215.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2443_CR4","doi-asserted-by":"publisher","first-page":"924058","DOI":"10.1155\/2011\/924058","volume":"2011","author":"YT Tai","year":"2011","unstructured":"Tai YT, Anderson KC. Antibody-based therapies in multiple myeloma. Bone Marrow Res. 2011;2011:924058.","journal-title":"Bone Marrow Res"},{"key":"2443_CR5","doi-asserted-by":"publisher","first-page":"949","DOI":"10.2217\/fon.14.56","volume":"10","author":"P Moreau","year":"2014","unstructured":"Moreau P, Touzeau C. Elotuzumab for the treatment of multiple myeloma. Future Oncol. 2014;10:949\u201356.","journal-title":"Future Oncol"},{"key":"2443_CR6","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","volume":"112","author":"YT Tai","year":"2008","unstructured":"Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112:1329\u201337.","journal-title":"Blood"},{"key":"2443_CR7","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840\u20138.","journal-title":"J Immunol"},{"key":"2443_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1517\/13543784.2014.889681","volume":"23","author":"JP Laubach","year":"2014","unstructured":"Laubach JP, Tai YT, Richardson PG, Anderson KC. Daratumumab granted breakthrough drug status. Expert Opin Investig Drugs. 2014;23:445\u201352.","journal-title":"Expert Opin Investig Drugs"},{"key":"2443_CR9","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","volume":"20","author":"J Deckert","year":"2014","unstructured":"Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vall\u00e9e F, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res. 2014;20:4574\u201383.","journal-title":"Clin Cancer Res"},{"key":"2443_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2741\/4202","volume":"19","author":"JG Berdeja","year":"2014","unstructured":"Berdeja JG. Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma. Front Biosci (Landmark Ed). 2014;19:163\u201370.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"2443_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.blre.2014.09.011","volume":"29","author":"DW Sherbenou","year":"2014","unstructured":"Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG 3rd, Liu B. The development of potential antibody-based therapies for myeloma. Blood Rev. 2014;29:81\u201391.","journal-title":"Blood Rev"},{"key":"2443_CR12","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"YT Tai","year":"2014","unstructured":"Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128\u201338.","journal-title":"Blood"},{"key":"2443_CR13","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","volume":"120","author":"JA Zonder","year":"2012","unstructured":"Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120:552\u20139.","journal-title":"Blood"},{"key":"2443_CR14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s12032-007-0007-y","volume":"24","author":"V Jurisic","year":"2007","unstructured":"Jurisic V, Srdic T, Konjevic G, Markovic O, Colovic M. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med Oncol. 2007;24:312\u20137.","journal-title":"Med Oncol"},{"key":"2443_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3324\/haematol.13690","volume":"94","author":"S Barbier","year":"2009","unstructured":"Barbier S, Chatre L, Bras M, Sancho P, Rou\u00e9 G, Virely C, et al. Caspase-independent type III programmed cell death in chronic lymphocytic leukemia: the key role of the F-actin cytoskeleton. Haematologica. 2009;94:507\u201317.","journal-title":"Haematologica"},{"key":"2443_CR16","first-page":"2143","volume":"119","author":"A Ivanov","year":"2009","unstructured":"Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009;119:2143\u201359.","journal-title":"J Clin Invest"},{"key":"2443_CR17","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1182\/blood-2010-07-296913","volume":"117","author":"W Alduaij","year":"2011","unstructured":"Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011;117:4519\u201329.","journal-title":"Blood"},{"key":"2443_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1756-8722-7-33","volume":"7","author":"CS Breton","year":"2014","unstructured":"Breton CS, Nahimana A, Aubry D, Macoin J, Moretti P, Bertschinger M, et al. A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies. J Hematol Oncol. 2014;7:33.","journal-title":"J Hematol Oncol"},{"key":"2443_CR19","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1038\/leu.2012.141","volume":"26","author":"D Kim","year":"2012","unstructured":"Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia. 2012;26:2538\u201345.","journal-title":"Leukemia"},{"key":"2443_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2119\/molmed.2013.00009","volume":"19","author":"A Chillemi","year":"2013","unstructured":"Chillemi A, Zaccarello G, Quarona V, Ferracin M, Ghimenti C, Massaia M, et al. Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule. Mol Med. 2013;19:99\u2013108.","journal-title":"Mol Med"},{"key":"2443_CR21","first-page":"1234","volume":"91","author":"R Bataille","year":"2006","unstructured":"Bataille R, Jego G, Robillard N, Barill\u00e9-Nion S, Harousseau JL, Moreau P, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of \u2018many and multiple myelomas\u2019 and of new targets for myeloma therapy. Haematologica. 2006;91:1234\u201340.","journal-title":"Haematologica"},{"key":"2443_CR22","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1038\/leu.2012.140","volume":"26","author":"D Kim","year":"2012","unstructured":"Kim D, Park CY, Medeiros BC, Weissman IL. CD19-CD45 low\/- CD38 high\/CD138+ plasma cells enrich for human tumorigenic myeloma cells. Leukemia. 2012;26:2530\u20137.","journal-title":"Leukemia"},{"key":"2443_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1182\/blood.V124.21.83.83","volume":"124","author":"T Martin III","year":"2014","unstructured":"Martin T III, Baz R, Benson DM Jr, Lendvai N, Campana F, Charpentier E, et al. A Phase Ib dose escalation trial of SAR650984 (Anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma. Blood. 2014;124:83.","journal-title":"Blood"},{"key":"2443_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/leu.2013.115","volume":"28","author":"YT Tai","year":"2014","unstructured":"Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28:155\u201365.","journal-title":"Leukemia"},{"key":"2443_CR25","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1182\/blood-2006-12-061812","volume":"109","author":"S Deaglio","year":"2007","unstructured":"Deaglio S, Vaisitti T, Billington R, Bergui L, Omede P, Genazzani AA, et al. CD38\/CD19: a lipid raft-dependent signaling complex in human B cells. Blood. 2007;109:5390\u20138.","journal-title":"Blood"},{"key":"2443_CR26","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1182\/blood-2011-12-395541","volume":"119","author":"J Honeychurch","year":"2012","unstructured":"Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A, et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood. 2012;119:3523\u201333.","journal-title":"Blood"},{"key":"2443_CR27","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","volume":"124","author":"JL van Bueren","year":"2014","unstructured":"van Bueren JL, Jakobs D, Kaldenhoven N, Roza M, Hiddingh S, Meesters J, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood. 2014;124:3474.","journal-title":"Blood"},{"key":"2443_CR28","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1242\/jcs.091181","volume":"126","author":"S Aits","year":"2013","unstructured":"Aits S, Jaattela M. Lysosomal cell death at a glance. J Cell Sci. 2013;126:1905\u201312.","journal-title":"J Cell Sci"},{"key":"2443_CR29","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1084\/jem.20072152","volume":"205","author":"S Conus","year":"2008","unstructured":"Conus S, Perozzo R, Reinheckel T, Peters C, Scapozza L, Yousefi S, et al. Caspase-8 is activated by cathepsin D initiating neutrophil apoptosis during the resolution of inflammation. J Exp Med. 2008;205:685\u201398.","journal-title":"J Exp Med"},{"key":"2443_CR30","doi-asserted-by":"publisher","first-page":"19140","DOI":"10.1074\/jbc.M802513200","volume":"283","author":"G Droga-Mazovec","year":"2008","unstructured":"Droga-Mazovec G, Bojic L, Petelin A, Ivanova S, Romih R, Repnik U, et al. Cysteine cathepsins trigger caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2 homologues. J Biol Chem. 2008;283:19140\u201350.","journal-title":"J Biol Chem"},{"key":"2443_CR31","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1046\/j.1365-2567.2002.01495.x","volume":"107","author":"JP Deans","year":"2002","unstructured":"Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology. 2002;107:176\u201382.","journal-title":"Immunology"},{"key":"2443_CR32","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1189\/jlb.0704423","volume":"77","author":"B Drenou","year":"2005","unstructured":"Drenou B, Amiot L, Setterblad N, Taque S, Guilloux V, Charron D, et al. MHC class II signaling function is regulated during maturation of plasmacytoid dendritic cells. J Leukoc Biol. 2005;77:560\u20137.","journal-title":"J Leukoc Biol"},{"key":"2443_CR33","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012;119:2100\u20135.","journal-title":"Blood"},{"key":"2443_CR34","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1200\/JCO.2011.36.5726","volume":"30","author":"H Avet-Loiseau","year":"2012","unstructured":"Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del (17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012;30:1949\u201352.","journal-title":"J Clin Oncol"},{"key":"2443_CR35","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1182\/blood-2008-12-193458","volume":"114","author":"D Reece","year":"2009","unstructured":"Reece D, Song KW, Fu T, Roland B, Chang H, Horsman DE, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood. 2009;114:522\u20135.","journal-title":"Blood"},{"key":"2443_CR36","doi-asserted-by":"publisher","first-page":"532","DOI":"10.4065\/mcp.2009.0677","volume":"85","author":"P Kapoor","year":"2010","unstructured":"Kapoor P, Fonseca R, Rajkumar SV, Sinha S, Gertz MA, Stewart AK, et al. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapy. Mayo Clin Proc. 2010;85:532\u20137.","journal-title":"Mayo Clin Proc"},{"key":"2443_CR37","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1038\/leu.2014.102","volume":"28","author":"PJ Teoh","year":"2014","unstructured":"Teoh PJ, Chung TH, Sebastian S, Choo SN, Yan J, Ng SB, et al. p53 haploinsufficiency and functional abnormalities in multiple myeloma. Leukemia. 2014;28:2066\u201374.","journal-title":"Leukemia"},{"key":"2443_CR38","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.leukres.2003.12.008","volume":"28","author":"Y Matsuo","year":"2004","unstructured":"Matsuo Y, Drexler HG, Harashima A, Okochi A, Hasegawa A, Kojima K, et al. Induction of CD28 on the new myeloma cell line MOLP-8 with t(11;14)(q13;q32) expressing delta\/lambda type immunoglobulin. Leuk Res. 2004;28:869\u201377.","journal-title":"Leuk Res"},{"key":"2443_CR39","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1073\/pnas.0408592102","volume":"102","author":"H Erdal","year":"2005","unstructured":"Erdal H, Berndtsson M, Castro J, Brunk U, Shoshan MC, Linder S. Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proc Natl Acad Sci USA. 2005;102:192\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2443_CR40","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.canlet.2010.05.021","volume":"332","author":"L Groth-Pedersen","year":"2013","unstructured":"Groth-Pedersen L, Jaattela M. Combating apoptosis and multidrug resistant cancers by targeting lysosomes. Cancer Lett. 2013;332:265\u201374.","journal-title":"Cancer Lett"},{"key":"2443_CR41","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1042\/BST20140145","volume":"42","author":"AM Villamil Giraldo","year":"2014","unstructured":"Villamil Giraldo AM, Appelqvist H, Ederth T, Ollinger K. Lysosomotropic agents: impact on lysosomal membrane permeabilization and cell death. Biochem Soc Trans. 2014;42:1460\u20134.","journal-title":"Biochem Soc Trans"},{"key":"2443_CR42","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ccr.2013.08.003","volume":"24","author":"NH Petersen","year":"2013","unstructured":"Petersen NH, Olsen OD, Groth-Pedersen L, Ellegaard AM, Bilgin M, Redmer S, et al. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell. 2013;24:379\u201393.","journal-title":"Cancer Cell"},{"key":"2443_CR43","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature08710","volume":"463","author":"T Kirkegaard","year":"2010","unstructured":"Kirkegaard T, Roth AG, Petersen NH, Mahalka AK, Olsen OD, Moilanen I, et al. Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology. Nature. 2010;463:549\u201353.","journal-title":"Nature"},{"key":"2443_CR44","first-page":"1131","volume":"30","author":"AT Singh","year":"2010","unstructured":"Singh AT, Evens AM, Prachand SN, Gordon LI. Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines. Anticancer Res. 2010;30:1131\u20136.","journal-title":"Anticancer Res"},{"key":"2443_CR45","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1182\/blood-2014-11-612069","volume":"125","author":"X Leleu","year":"2015","unstructured":"Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, et al. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and\/or translocation (4;14): IFM 2010-02 trial results. Blood. 2015;125:1411\u201317.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02443-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02443-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02443-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:47:06Z","timestamp":1772023626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02443-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2443"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02443-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]},"assertion":[{"value":"22 October 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}